8-K: Viridian Therapeutics Announces Positive Phase 3 Results for Veligrotug in Thyroid Eye Disease

Viridian Therapeutics' veligrotug met all primary and secondary endpoints in a Phase 3 trial for chronic thyroid eye disease, showing significant improvements in proptosis, diplopia, and clinical activity scores.

Summary

• Viridian Therapeutics announced positive topline results from the THRIVE-2 Phase 3 trial for veligrotug in patients with chronic thyroid eye disease (TED).
• The trial met all primary and secondary endpoints at the 15-week primary analysis timepoint after five infusions of veligrotug.
• The study enrolled 188 patients, with 125 receiving veligrotug and 63 receiving a placebo.
• The mean time since onset of TED in the patient population was 69.8 months.
• Veligrotug showed a 56% proptosis responder rate compared to 8% for placebo, a 48% placebo-adjusted difference.
• The mean reduction in proptosis was 2.34mm for veligrotug versus 0.46mm for placebo, a 1.9mm placebo-adjusted difference.
• A 56% diplopia response rate was observed in the veligrotug group compared to 25% in the placebo group, a 31% placebo-adjusted difference.
• Complete resolution of diplopia was achieved in 32% of veligrotug patients versus 14% of placebo patients, an 18% placebo-adjusted difference.
• 54% of veligrotug patients achieved a maximal or near-maximal therapeutic effect on the Clinical Activity Score (CAS), compared to 24% of placebo patients, a 29% placebo-adjusted difference.
• The mean reduction in CAS was 2.9 points for veligrotug versus 1.3 points for placebo, a 1.6-point placebo-adjusted difference.
• The overall responder rate was 56% for veligrotug compared to 7% for placebo, a 50% placebo-adjusted difference.
• Veligrotug was generally well-tolerated, with 94% of patients completing their treatment course.
• The most common adverse events included muscle spasms (36% vs 6% for placebo), headache (14% vs 13%), and hearing impairment (13% vs 3%).

Sentiment

Score: 9

Explanation: The document presents overwhelmingly positive results from a Phase 3 trial, with strong efficacy and a good safety profile. The company's financial position is also strong, and management is optimistic about the future. The only minor negative is the higher incidence of some side effects, but overall the sentiment is very positive.

Positives

• Veligrotug demonstrated statistically significant and clinically meaningful improvements in proptosis, diplopia, and CAS.
• The drug showed a rapid onset of response, with improvements seen as early as three weeks for proptosis and six weeks for diplopia.
• The safety profile of veligrotug was consistent with previous studies and was generally well-tolerated.
• The high completion rate of 94% indicates good tolerability and patient adherence.
• The company's strong cash position provides financial stability through the anticipated commercial launch of veligrotug.
• The results support the potential of veligrotug to become a market-leading therapy for TED.
• The data suggests veligrotug could be the only approved therapy with data in chronic patients included in the labeling.

Negatives

• Some adverse events occurred at a higher frequency in the veligrotug group, including muscle spasms (36%), hearing impairment (13%), and menstrual disorders (33% in menstruating women).
• Hearing impairment had a 9.6% placebo-adjusted rate, which is a notable side effect.

Risks

• The company is subject to risks related to clinical drug development, including potential delays and regulatory hurdles.
• There is competition from other therapies or products in the market.
• Manufacturing risks could impact the supply of the drug.
• The company's future financial performance is subject to various uncertainties.
• The commercial success of veligrotug is not guaranteed, even if approved.

Future Outlook

The company anticipates a BLA submission for veligrotug in the second half of 2025 and topline data for VRDN-003 in the first half of 2026, with a BLA submission by the end of 2026. The company believes veligrotug has the potential to become a market-leading therapy for TED.

Management Comments

• Steve Mahoney, Viridian's President and CEO, stated that the THRIVE-2 results were better than expected and confirm the potential of veligrotug to be the treatment-of-choice for all forms of active and chronic TED.
• Steven Leibowitz, M.D., a THRIVE-2 investigator, noted that the results are highly encouraging and that resolving double vision can change patients' lives.
• Tony Casciano, Chief Commercial Officer, believes veligrotug is positioned to become a market-leading TED therapeutic due to its strong data, favorable safety profile, and shorter dosing regimen.

Industry Context

This announcement is significant as it presents positive Phase 3 data for a potential new treatment for thyroid eye disease, a condition with limited treatment options. The results position Viridian as a strong competitor in the TED market, potentially challenging existing therapies.

Comparison to Industry Standards

• The 56% proptosis responder rate for veligrotug is significantly higher than the 8% observed in the placebo group, indicating a strong treatment effect compared to no treatment.
• The 56% diplopia response rate and 32% complete resolution rate are notable, as this is the first product candidate to demonstrate such results in a global chronic TED phase 3 study.
• The 94% treatment completion rate suggests a favorable tolerability profile, which is important for patient adherence compared to other treatments with higher discontinuation rates.
• The rapid onset of response, with improvements seen as early as three weeks for proptosis and six weeks for diplopia, is a key differentiator compared to other therapies that may take longer to show effects.
• The company's claim that veligrotug could be the only approved therapy with data in chronic patients included in the labeling highlights a potential competitive advantage over other treatments that may not have been studied in this specific patient population.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical trial results and the potential for a new market-leading therapy.
• Patients with TED may benefit from a new treatment option with a rapid onset of action and significant improvements in symptoms.
• Employees may be motivated by the positive results and the company's progress.
• The company's strong cash position provides financial stability for future operations.

Next Steps

• The company will proceed with a BLA submission for veligrotug in the second half of 2025.
• The company will continue dosing patients in the REVEAL-1 and REVEAL-2 trials for VRDN-003.
• Topline data from the REVEAL-1 and REVEAL-2 trials are expected in the first half of 2026.
• A BLA submission for VRDN-003 is anticipated by the end of 2026.

Key Dates

Keywords

Thyroid Eye Disease, Veligrotug, VRDN-001, VRDN-003, Proptosis, Diplopia, Clinical Activity Score, IGF-1R, Phase 3 Trial, Biopharmaceutical